|  | 
|  | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhaseApproved | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
 / Active, not recruitingPhase 4 A Retrospective Study of the Efficacy and Safety of Hema-Plus (Recombinant Human Erythropoietin Alfa) in Patients with Chronic Kidney Disease who continuously used Hema-Plus at Siriraj Hospital
A Prospective Study on Efficacy and Safety of Filgrastim (Leuco-Plus 300) for Prevention of Chemotherapy Induced Neutropenia in Patients with Diffuse Large B-Cell Lymphoma
A Study to Observe Pure Red Cell Aplasia (PRCA) Occurrence in Patients with Chronic Kidney Disease Who Used Hema-Plus (Recombinant Human Erythropoietin Alfa) at Ramathibodi Hospital
100 Clinical Results associated with Apexcela Co., Ltd.
0  Patents (Medical) associated with Apexcela Co., Ltd.
100 Deals associated with Apexcela Co., Ltd.
100 Translational Medicine associated with Apexcela Co., Ltd.